诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09969 诺诚健华

休市中 07-24 16:08:05

13.800

-0.430

-3.02%

最高14.400	最低13.680	成交量406.82万
今开14.290	昨收14.230	日振幅5.06%
总市值243.85亿	流通市值206.17亿	总股本17.67亿
成交额5,634万	换手率0.27%	流通股本14.94亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":13.8,"timestamp":1784880485009,"preClose":14.23,"halted":0,"volume":4068247,"delay":0,"changeRate":-0.030217849613492602,"floatShares":1494000000,"shares":1767000000,"eps":0.38,"marketStatus":"休市中","change":-0.43,"latestTime":"07-24 16:08:05","open":14.29,"high":14.4,"low":13.68,"amount":56343229,"amplitude":0.050597,"askPrice":13.81,"askSize":20000,"bidPrice":13.8,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":0.469,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785115800000},"marketStatusCode":7,"adr":0,"listingDate":1584892800000,"exchange":"SEHK","adjPreClose":14.23,"openAndCloseTimeList":[[1784856600000,1784865600000],[1784869200000,1784880000000]],"volumeRatio":0.4827339126277398,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":27.68,"timestamp":1784876400000,"preClose":28.36,"halted":0,"volume":8694600,"delay":0,"premium":"-56.90"}},"requestUrl":"/m/hq/s/09969/tweets","defaultTab":"tweets","newsList":[{"id":"2653737746","title":"BMS的留白，诺诚健华的窗口","url":"https://stock-news.laohu8.com/highlight/detail?id=2653737746","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653737746?lang=zh_cn&edition=full","pubTime":"2026-07-22 15:36","pubTimestamp":1784705799,"startTime":"0","endTime":"0","summary":"更关键的产业意义在于：全球第一个用于特应性皮炎的TYK2抑制剂，大概率将出自诺诚健华之手。BMS的留白，诺诚健华的窗口全球TYK2先驱BMS的Deucravacitinib选择了另一条路：聚焦银屑病、银屑病关节炎、系统性红斑狼疮，未大规模开展针对特应性皮炎的关键注册临床。BMS这一战略留白，恰好让出了一道窄门。在特应性皮炎这条BMS放弃的赛道上，诺诚健华的坚持正在得到回报。全球权益的含金量一个值得注意的事实是，诺诚健华至今仍持有ICP-332的全部全球权益。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1784604125251670229","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BMS","09969","BK1161","BK1574","688428","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145405224","title":"港股直击 | 生物医药股走强，康方生物涨近7%，荣昌生物涨超4%，泰格医药、诺诚健华涨近3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145405224","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145405224?lang=zh_cn&edition=full","pubTime":"2026-07-22 10:11","pubTimestamp":1784686287,"startTime":"0","endTime":"0","summary":"7月22日，港股生物医药股走强，康方生物涨近7%，荣昌生物涨超4%，泰格医药、诺诚健华涨近3%，复宏汉霖、药明康德、君实生物涨超2%。消息面上，美国总统特朗普当地时间7月21日在社交媒体发文表示，自2026.8.1起，所有进口到美国的仿制药将在未来两年内继续适用零关税。两年期满后，相关产品将被征收100%的关税，期限为一年。此后，关税将进一步提高至200%。","market":"hk","thumbnail":"https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股直击 | 生物医药股走强，康方生物涨近7%，荣昌生物涨超4%，泰格医药、诺诚健华涨近3%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347","02359","09995","09926","01877","02696","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160890587","title":"诺诚健华三位高管完成31.88万股A股减持 兑现资金约902.07万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1160890587","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160890587?lang=zh_cn&edition=full","pubTime":"2026-07-20 18:40","pubTimestamp":1784544049,"startTime":"0","endTime":"0","summary":"2026年7月21日，诺诚健华医药有限公司公告，公司董事及高级管理人员已按照既定计划完成A股股份减持，累计减持318,750股，占公司当前总股本的0.0180%。此次减持均通过集中竞价方式于2026年7月17日完成，合计套现约902.07万元。截至公告披露日，三位高管的减持计划已实施完毕，后续如有新的股份变动，公司将按规定及时履行信息披露义务。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652371542","title":"每周股票复盘：诺诚健华（688428）Soficitinib治疗特应性皮炎Ⅲ期达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2652371542","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652371542?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:32","pubTimestamp":1784395931,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，诺诚健华报收于26.52元，较上周的29.78元下跌10.95%。本周关注点公司公告汇总：Soficitinib治疗中重度特应性皮炎Ⅲ期注册性临床试验达到主要终点。公司公告汇总诺诚健华自主研发的新一代高选择性口服TYK2抑制剂soficitinib治疗成人中重度特应性皮炎的III期注册性临床试验达到主要终点，疗效在统计学上高度显著，并具临床意义，多个次要终点也达成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000264.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","BK1574","688428","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652209405","title":"7月17日诺诚健华跌9.21%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652209405","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652209405?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:29","pubTimestamp":1784276985,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日诺诚健华跌9.21%，收盘报26.52元，换手率8.86%，成交量24.17万手，成交额6.64亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共28家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为31.86亿元，最新净值3.7269，较上一交易日上涨0.34%，近一年上涨10.42%。富国精准医疗混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK1574","BK0239","BK1161","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195426870","title":"异动解读｜诺诚健华盘中下跌5.04%，生物科技板块集体走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1195426870","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195426870?lang=zh_cn&edition=full","pubTime":"2026-07-17 10:53","pubTimestamp":1784256828,"startTime":"0","endTime":"0","summary":"7月17日，诺诚健华盘中下跌5.04%，报13.85港元，成交额8414.04万港元。公司所在生物科技板块今日集体大幅走弱，同板块康方生物跌12.18%、三生制药跌11.84%、科伦博泰生物跌6.79%、信达生物跌5.79%、百济神州跌2.67%，行业个股普遍承压。消息面上，公司于7月15日及7月16日连续披露Soficitinib治疗中重度特应性皮炎III期研究及非节段型白癜风II期研究均达到主要终点的积极结果，但短期利好兑现叠加板块系统性回调，股价出现回落。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116693797","title":"诺诚健华（09969.HK）Soficitinib治疗非节段型白癜风II期试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1116693797","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116693797?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:46","pubTimestamp":1784191592,"startTime":"0","endTime":"0","summary":"2026年7月16日，诺诚健华医药有限公司发布自愿公告称，公司自主研发的新一代口服TYK2抑制剂Soficitinib在治疗非节段型白癜风成人患者的II/III期适应性临床研究II期部分达到主要终点。本次披露结果仅涉及II期部分。公司特别提示，根据香港联交所证券上市规则第18A.08条，Soficitinib最终未必能够成功开发、上市及/或商业化治疗白癜风。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651417153","title":"诺诚健华(688428.SH)：Soficitinib(ICP-332)治疗非节段型白癜风Ⅱ期研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2651417153","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651417153?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:42","pubTimestamp":1784191344,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华 发布公告，公司自主研发的新一代高选择性口服酪氨酸激酶2抑制剂soficitinib用于治疗非节段型白癜风患者的II/III期适应性临床研究中，II期阶段成功达到主要终点，并取得积极顶线结果。Soficitinib是公司自主研发的新一代高选择性口服TYK2抑制剂。TYK2属于Janus激酶家族成员，在白细胞介素-12/IL-23家族细胞因子受体及I型干扰素受体下游信号传导过程中发挥重要作用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468424.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","BK0239","09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651469258","title":"诺诚健华（688428）披露2023年人民币股份激励计划归属结果，7月15日股价下跌2.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651469258","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651469258?lang=zh_cn&edition=full","pubTime":"2026-07-15 22:07","pubTimestamp":1784124436,"startTime":"0","endTime":"0","summary":"截至2026年7月15日收盘，诺诚健华报收于29.63元，较前一交易日下跌2.18%，最新总市值为524.19亿元。该股当日开盘30.31元，最高31.9元，最低29.12元，成交额达7.09亿元，换手率为8.46%。近日，诺诚健华医药有限公司根据2023年人民币股份激励计划的归属结果，向2名董事、1名高级管理人员及132名激励对象发行新人民币股份，合计1,644,750股，每股发行价为人民币6.95元。本次发行后，公司已发行股份总数由2026年6月30日的1,764,576,252股增至1,766,221,002股。此次变动未导致库存股份变动。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500044610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK1574","UCmain","MCNHmain","CNHmain","CYB","BK1161","BK0239","688428","MUCmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145178000","title":"诺诚健华（09969）口服TYK2抑制剂Soficitinib在中重度特应性皮炎III期试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1145178000","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145178000?lang=zh_cn&edition=full","pubTime":"2026-07-15 19:05","pubTimestamp":1784113553,"startTime":"0","endTime":"0","summary":"2026年7月15日，诺诚健华医药有限公司发布自愿公告称，公司自主研发的新一代口服酪氨酸激酶2抑制剂Soficitinib治疗中重度特应性皮炎的III期注册性临床试验成功达到其主要终点。该结果具备统计学显著性，并带来具有临床意义的改善，同时在多项次要终点上亦取得积极结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651452404","title":"诺诚健华(09969)：soficitinib (ICP-332)治疗中重度特应性皮炎的 III期注册性试验成功达到其主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2651452404","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651452404?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:58","pubTimestamp":1784113097,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华 公布，公司自主研发的新一代口服酪氨酸激酶2抑制剂soficitinib ，用于治疗中重度特应性皮炎患者的III期注册性临床试验成功达到其主要终点。研究结果显示，soficitinib 达到主要终点，在统计学上具有显著性，并取得具有临床意义的改善。公司将继续完成正在进行中的III期研究，包括长期安全性随访，并计划于研究完成后推进soficitinib 用于治疗中重度特应性皮炎的注册申报工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK4134","III","09969","688428","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651453905","title":"诺诚健华(09969.HK)根据2023年人民币股股份激励计划合计发行204.48万股新人民币股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2651453905","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651453905?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:28","pubTimestamp":1784104085,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09969","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142084611","title":"诺诚健华：7月15日发行2,044,750股人民币股份 用于股权激励","url":"https://stock-news.laohu8.com/highlight/detail?id=1142084611","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142084611?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:26","pubTimestamp":1784104017,"startTime":"0","endTime":"0","summary":"诺诚健华医药有限公司于2026年7月15日发布翌日披露报表。公告显示，公司在香港联交所上市的普通股数量维持1,493,798,235股不变，库藏股数为2,486,000股。与此同时，公司根据2023年人民币股股份激励计划，于上海证券交易所科创板增发人民币普通股2,044,750股，每股发行价为人民币6.95元。此次增发涉及向2名董事、1名高级管理人员及多批激励对象共授予2,044,750股人民币普通股，占发行前公司已发行股份总数的约0.12%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺诚健华：7月15日发行2,044,750股人民币股份 用于股权激励","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147767494","title":"异动解读｜诺诚健华盘中上涨5.09%，生物科技板块集体走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1147767494","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147767494?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:56","pubTimestamp":1784080595,"startTime":"0","endTime":"0","summary":"7月15日，诺诚健华盘中上涨5.09%，报15.08港元，成交额5614.91万港元。消息面上，生物科技板块今日集体走强，行业个股普涨。同板块中，科伦博泰生物涨9.9%，康方生物涨8.5%，信达生物涨7.5%，三生制药涨6.96%，百济神州涨2.85%。公司层面，诺诚健华近期研发进展密集：靶向CDH17的新型ADC创新药ICP-B208已完成首例患者给药，临床数据刊登国际学术期刊；此外，公司2023年科创板限制性股票激励计划归属的204.48万股新增股份于今日上市流通。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650815490","title":"每周股票复盘：诺诚健华（688428）科创板股份归属上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2650815490","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650815490?lang=zh_cn&edition=full","pubTime":"2026-07-12 02:32","pubTimestamp":1783794729,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，诺诚健华报收于29.78元，较上周的30.18元下跌1.33%。本周关注点来自公司公告汇总：诺诚健华完成2023年科创板限制性股票激励计划部分归属，新增股份2,044,750股于2026年7月15日上市。诺诚健华医药有限公司完成2023年科创板限制性股票激励计划首次授予部分第三个归属期及预留授予部分第二个归属期的股份登记工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000813.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","BK1574","09969","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650010135","title":"诺诚健华（688428）披露2023年科创板限制性股票激励计划归属结果暨股份上市公告，7月10日股价上涨2.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650010135","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650010135?lang=zh_cn&edition=full","pubTime":"2026-07-10 22:29","pubTimestamp":1783693755,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，诺诚健华报收于29.78元，较前一交易日上涨2.34%，最新总市值为526.23亿元。公告显示，公司已完成2023年科创板限制性股票激励计划首次授予部分第三个归属期及预留授予部分第二个归属期的股份登记工作。本次归属合计134人，归属股票数量为2,044,750股，来源为公司向激励对象定向发行人民币普通股股票。上市流通日为2026年7月15日。安永华明会计师事务所已完成验资，公司已收到激励对象缴纳的合计人民币14,211,012.50元出资款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000044628.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","688428","BK0239","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194654207","title":"诺诚健华204.48万股限制性股票将于7月15日登陆科创板","url":"https://stock-news.laohu8.com/highlight/detail?id=1194654207","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194654207?lang=zh_cn&edition=full","pubTime":"2026-07-10 18:11","pubTimestamp":1783678280,"startTime":"0","endTime":"0","summary":"7月11日，诺诚健华医药有限公司公告称，公司2023年科创板限制性股票激励计划中首次授予部分第三个归属期及预留授予部分第二个归属期的限制性股票已完成股份登记，共计2,044,750股A股将于2026年7月15日上市流通。2026年一季度，诺诚健华归属于上市公司股东的净利润为105,817,401.83元，对应基本每股收益为0.06元；在发行股份增加至1,769,107,002股且净利润保持不变的情况下，基本每股收益将相应下降。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650667188","title":"港股异动 | 诺诚健华(09969.HK)盘中涨超5% CDH17靶向ADC新药ICP-B208完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2650667188","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650667188?lang=zh_cn&edition=full","pubTime":"2026-07-10 15:53","pubTimestamp":1783670006,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","09969","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158706937","title":"异动解读｜诺诚健华盘中上涨5.07%，港股创新药板块集体拉升","url":"https://stock-news.laohu8.com/highlight/detail?id=1158706937","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158706937?lang=zh_cn&edition=full","pubTime":"2026-07-10 11:17","pubTimestamp":1783653456,"startTime":"0","endTime":"0","summary":"7月10日，诺诚健华盘中上涨5.07%，报14.09港元，成交额7312.06万港元。消息面上，港股创新药概念股盘中集体拉升，荣昌生物、诺诚健华涨超5%，药明康德、药明生物、亚盛医药涨超4%，恒瑞医药涨超3%，板块资金回流明显。公司层面，诺诚健华此前宣布自主研发的靶向CDH17新型ADC创新药ICP-B208完成首例患者给药，正式进入临床阶段，全球尚无CDH17靶向ADC新药上市，该管线差异化优势突出。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180945737","title":"港股创新药概念股盘中拉升，荣昌生物、诺诚健华涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180945737","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180945737?lang=zh_cn&edition=full","pubTime":"2026-07-10 10:01","pubTimestamp":1783648919,"startTime":"0","endTime":"0","summary":"7月10日，港股创新药概念股盘中拉升，$荣昌生物(09995)$、$诺诚健华(09969)$涨超5%，$药明康德(02359)$、$药明生物(02269)$、$亚盛医药(06855)$、$乐普生物(02157)$涨超4%，$恒瑞医药(01276)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","688331","159992","BK1574","LU1064131003.USD","BK1583","LU2488822045.USD","06978","09995","LU1969619763.USD","BK4585","09969","LU2148510915.USD","MEDX","KCAI","LU1064130708.USD","BK4588","LU2328871848.SGD","BK0239","VXUS","688428","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"https://cn.innocarepharma.com","stockEarnings":[{"period":"1week","weight":-0.0007},{"period":"1month","weight":0.2849},{"period":"3month","weight":-0.0612},{"period":"6month","weight":0.1685},{"period":"1year","weight":-0.2308},{"period":"ytd","weight":0.122}],"compareEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":0.0662},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0668},{"period":"1year","weight":-0.0274},{"period":"ytd","weight":-0.026}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在未满足临床需求的领域。该公司的主要产品管线包括奥布替尼、Tafasitamab、ICP-490、ICP-B02、ICP-248、ICP-B05、ICP-332、ICP-488、ICP-192、ICP-723、ICP-033和ICP-189等。其产品主要用于治疗血液瘤、实体瘤和自身免疫疾病。该公司还在开发用于治疗由T细胞功能异常所导致的自身免疫性疾病的产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.103999},{"month":2,"riseRate":0.666667,"avgChangeRate":0.128923},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.010195},{"month":4,"riseRate":0.714286,"avgChangeRate":0.102464},{"month":5,"riseRate":0.142857,"avgChangeRate":-0.059233},{"month":6,"riseRate":0.857143,"avgChangeRate":0.113731},{"month":7,"riseRate":0.571429,"avgChangeRate":0.057018},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.082108},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.024907},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.033299},{"month":11,"riseRate":0.833333,"avgChangeRate":0.100833},{"month":12,"riseRate":0.5,"avgChangeRate":-0.012645}],"exchange":"SEHK","name":"诺诚健华","nameEN":"INNOCARE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,09969,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}